Results 231 to 240 of about 81,723 (303)

Combination of Janus kinase inhibitor and biologic for recalcitrant severe atopic dermatitis. [PDF]

J Eur Acad Dermatol Venereol
De Greef A, Baeck M.
europepmc   +1 more source

Efficacy of abrocitinib and dupilumab in itch‐dominant atopic dermatitis: An analysis of 2 trials

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Jonathan I. Silverberg, Marjolein de Bruin‐Weller, Javier Ortiz de Frutos, Juan Francisco Silvestre, Brian Esparza, Daniela E. Myers, Pinaki Biswas, Irene Hernández‐Martín, Erman Güler, Marina Mikheil, Raj Chovatiya   +10 more
wiley   +1 more source

Porphyromonas gingivalis Outer Membrane Vesicles‐Associated DNA Triggers Inflammation by Inducing IL‐6 in Astrocytes

Molecular Oral Microbiology, EarlyView.
Pg releases OMVs which contain Pg genomic DNA. The Pg OMVs‐associated DNA is incorporated into astrocytes via endocytosis and increases IL‐6 mRNA expression via TLR9. These effects of Pg OMVs may induce neuroinflammation, which could contribute to the onset and progression of AD in periodontal disease.
Ayu Takai, Kaya Yoshida, Yuka Hiroshima, Ayu Ikuta, Mariko Seyama, Yuta Uemura, Hiromichi Yumoto, Kazumi Ozaki   +7 more
wiley   +1 more source

A case of pneumonia caused by infection with Tropheryma whipplei complicated by cryptococcus during treatment with a Janus kinase inhibitor: a case report. [PDF]

BMC Pulm Med
Shan X, Li Z, Dong L.
europepmc   +1 more source

Fatal Chronic Varicella‐Zoster Viral Infection in a Young Man With Chediak–Higashi Syndrome

Pediatric Dermatology, EarlyView.
ABSTRACT Chediak–Higashi syndrome (CHS) is a rare autosomal recessive primary immunodeficiency characterized by partial oculocutaneous albinism, neurologic involvement, and a predisposition to severe infections. Patients are particularly susceptible to developing hemophagocytic lymphohistiocytosis (HLH), which significantly worsens prognosis. We report
Albane Badet, Clément Pruvot, Zoé Manssens, Wadih Abou‐Chahla, Sébastien Buche   +4 more
wiley   +1 more source

Systemic Treatment with the Janus Kinase Inhibitor Baricitinib in Ocular Chronic Graft-versus-Host Disease. [PDF]

Ophthalmol Sci
McManus T, Holtzman NG, Zhao A, Cousineau-Krieger C, Vitale S, FitzGibbon EJ, Payne D, Newgen J, Igbinosun C, Im AP, Peer C, Figg WD, Cowen EW, Mays JW, Pavletic S, Magone MT.   +15 more
europepmc   +1 more source

Prolonged ruxolitinib cream treatment for vitiligo among patients with no or limited response in the first 6 months

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Albert Wolkerstorfer, Melinda J. Gooderham, Michael Sebastian, David Rosmarin, Andrew Blauvelt, Maryam Shayesteh Alam, Jacek Zdybski, Shaoceng Wei, Deanna Kornacki, Thierry Passeron, John E. Harris   +10 more
wiley   +1 more source

Janus Kinase Inhibitors for the Treatment of Pediatric Morphea: A Systematic Review

Pediatric Dermatology, EarlyView.
ABSTRACT Morphea, also known as localized scleroderma (LoS), is an inflammatory, fibrosing dermatologic disorder of the skin and underlying tissues with associated comorbidities including joint contractures, limb‐length discrepancies, and inflammatory arthropathy occurring more commonly in children.
Alexa Moschella, Celina DeBiasio, Carmen Liy‐Wong   +2 more
wiley   +1 more source

Preclinical and clinical evaluation of the Janus Kinase inhibitor ruxolitinib in multiple myeloma. [PDF]

Oncotarget
Del Dosso A, Tadevosyan E, Berenson JR.
europepmc   +1 more source